Greg Everson, M.D., FACP
Dr. Everson is Chief Executive Officer of HepQuant, LLC, a company he founded in 2007 with a small group of investors.
Dr. Everson received his MD degree from Cornell Medical College, NY, NY and is currently Past Professor of Medicine and Past Director of Hepatology at the University of Colorado, Denver. He is a distinguished Fellow of several professional societies and has published over 300 original papers, books, and book chapters in peer-reviewed journals that include Hepatology, Clinics in Liver Disease, Gastroenterology, Journal of Hepatology, New England Journal of Medicine, The American Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, and Expert Reviews in Gastroenterology and Hepatology. He has authored several “self-help” books on a variety of liver diseases: Living with Hepatitis C: A Survivor’s Guide, Curing Hepatitis C, Living with Hepatitis B: A Survivor’s Guide, and Living with Hemochromatosis: Answers to your Questions about Iron Overload.
He is a frequently invited speaker and has presented his work at clinical and scientific meetings nationally and internationally. His research has spanned many topics in both basic and clinical hepatology – bile acid and cholesterol metabolism, mechanisms of gallstone formation, effects of female steroid hormones on liver metabolism, hepatitis C, liver transplantation, polycystic disease, and quantifying the function of the liver with unique minimally invasive tests.
He is an advisor and consultant to foundations and industry. Dr. Everson is a member of the American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), American Society of Transplantation (AST), the International Liver Transplant Society (ILTS). He is past member of the Transplant Hepatology Committees of the American Board of Internal Medicine and Accreditation Council for Graduate Medical Education. After over twenty years of research, Dr. Everson founded HepQuant, LLC in order to commercialize his invention of novel technology for noninvasive assessment of chronic liver disease.